Stock SNBP PANBELA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Panbela Therapeutics, Inc.

Equities

SNBP

US69833W4042

Market Closed - OTC Markets
Other stock markets
 20:52:50 26/06/2024 BST 		5-day change 1st Jan Change
0.3813 USD -0.97% Intraday chart for Panbela Therapeutics, Inc. -5.85% -97.92%
06-24 Panbela Therapeutics Announces Third Independent Safety Review of Phase 3 ASPIRE Clinical Trial DSMB Recommended Continuation with No Trial Modification CI
06-10 Panbela Therapeutics, Inc. Announces Oral Presentation at Digestive Disease Week CI

Highlights

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Panbela Therapeutics Announces Third Independent Safety Review of Phase 3 ASPIRE Clinical Trial DSMB Recommended Continuation with No Trial Modification
CI
Panbela Therapeutics, Inc. Announces Oral Presentation at Digestive Disease Week
CI
North American Morning Briefing : The "Everything -2-
DJ
Panbela Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Panbela Therapeutics, Inc. Announces Interim Data Analysis for its Ongoing ASPIRE Trial Pushed to First Quarter of 2025
CI
Panbela Announces Poster Presentation At American Association for Cancer Research
CI
Panbela Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Panbela Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell on Expectations for Unchanged Fed Policy Rate
MT
Panbela Therapeutics, Inc. Exceeds 50% Enrollment for Aspire Trial in Pancreatic Cancer, Exceeding Anticipated Timelines with Accelerated Momentum
CI
Panbela Therapeutics, Inc. Announces Publication of Clinical Data Titled: Phase 1 Study of High-Dose DFMO, Celecoxib, Cyclophosphamide and Topotecan for Patients with Relapsed Neuroblastoma
CI
Panbela Therapeutics, Inc. Announces second Independent Safety Review of the ASPIRE Registration Clinical Trial
CI
Panbela Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Panbela Announces Publication of Preclinical and Clinical Data Titled: Inhibition of Polyamine Biosynthesis Preserves B Cell Function in Type 1 Diabetes
CI
Panbela Therapeutics, Inc. Announces Acceptance of Polyamine Inhibitor Car-T Combination Abstract for Online Publication
CI
Panbela Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Panbela Therapeutics, Inc. Opens Enrollment in UK and Germany for Aspire Trial in Pancreatic Cancer
CI
Panbela Therapeutics Divests Neuroblastoma Assets in Deal Valued at Up to $9.5 Million
MT
Panbela Announces Preliminary Safety Analysis for ASPIRE Trial
CI
Panbela Therapeutics, Inc. Announces PACES S0820 Phase III Trial Passes Pre-Planned Futility Analysis
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SNBP Stock
  4. News Panbela Therapeutics, Inc.
  5. Highlights